PC2 (D1E1S) XP® Rabbit mAb #14013
- WB
- IP
- IHC
- IF
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 65-75 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| Immunohistochemistry (Paraffin) | 1:3200 |
| Immunofluorescence (Frozen) | 1:800 |
| Immunofluorescence (Immunocytochemistry) | 1:800 |
Storage
For a carrier free (BSA and azide free) version of this product see product #33990.
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Background
Unlike what is observed with furin whose gene invalidation is lethal, inactivation of mouse PC2 by the introduction of a neomycin resistance gene into the third exon of the PCSK2 gene does not alter mouse viability (4). PC2 inactivation leads to alteration of the pancreatic islet cells, in agreement with the involvment of PC2 in the conversion of pro-insulin and pro-glucagon (5). PC2 is also responsible for the processing of several neuroendocrine peptide precursors such as pro-CCK, POMC, and neurotensin (6).
- Scamuffa, N. et al. (2006) FASEB J 20, 1954-63.
- Fugère, M. and Day, R. (2005) Trends Pharmacol Sci 26, 294-301.
- Seidah, N.G. and Chrétien, M. (1999) Brain Res 848, 45-62.
- Rouillé, Y. et al. (1995) Front Neuroendocrinol 16, 322-61.
- Steiner, D.F. et al. (1996) Diabetes Metab 22, 94-104.
- Scamuffa, N. et al. (2006) FASEB J 20, 1954-63.
- Moffett, R.C. et al. (2014) PLoS One 9, e96863.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.